These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 26694550)

  • 1. HEADROOM APPROACH TO DEVICE DEVELOPMENT: CURRENT AND FUTURE DIRECTIONS.
    Girling A; Lilford R; Cole A; Young T
    Int J Technol Assess Health Care; 2015 Jan; 31(5):331-8. PubMed ID: 26694550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early-stage valuation of medical devices: the role of developmental uncertainty.
    Girling A; Young T; Brown C; Lilford R
    Value Health; 2010 Aug; 13(5):585-91. PubMed ID: 20412542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probability elicitation to inform early health economic evaluations of new medical technologies: a case study in heart failure disease management.
    Cao Q; Postmus D; Hillege HL; Buskens E
    Value Health; 2013 Jun; 16(4):529-35. PubMed ID: 23796286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HEADROOM BEYOND THE QUALITY- ADJUSTED LIFE-YEAR: THE CASE OF COMPLEX PEDIATRIC NEUROLOGY.
    van Nimwegen KJM; Lilford RJ; van der Wilt GJ; Grutters JPC
    Int J Technol Assess Health Care; 2017 Jan; 33(1):5-10. PubMed ID: 28554333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pricing of medical devices under coverage uncertainty--a modelling approach.
    Girling AJ; Lilford RJ; Young TP
    Health Econ; 2012 Dec; 21(12):1502-7. PubMed ID: 22021085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating health economics modeling in the product development cycle of medical devices: a Bayesian approach.
    Vallejo-Torres L; Steuten LM; Buxton MJ; Girling AJ; Lilford RJ; Young T
    Int J Technol Assess Health Care; 2008; 24(4):459-64. PubMed ID: 18828941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Headroom Analysis for Early Economic Evaluation: A Systematic Review.
    Boudewijns EA; Otten TM; Gobianidze M; Ramaekers BL; van Schayck OCP; Joore MA
    Appl Health Econ Health Policy; 2023 Mar; 21(2):195-204. PubMed ID: 36575333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical device reimbursement coverage and pricing rules in Korea: current practice and issues with access to innovation.
    Lee SS; Salole E
    Value Health; 2014 Jun; 17(4):476-81. PubMed ID: 24969010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
    Siebert U; Rochau U; Claxton K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.
    Dranitsaris G; Ortega A; Lubbe MS; Truter I
    J Oncol Pharm Pract; 2012 Mar; 18(1):57-67. PubMed ID: 21382915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs.
    Rothery C; Claxton K; Palmer S; Epstein D; Tarricone R; Sculpher M
    Health Econ; 2017 Feb; 26 Suppl 1():109-123. PubMed ID: 28139090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health economics of medical devices: opportunities and challenges.
    Simoens S
    J Med Econ; 2008; 11(4):713-7. PubMed ID: 19450077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEDICAL DEVICE PRICES IN ECONOMIC EVALUATIONS.
    Akpinar I; Jacobs P; Husereau D
    Int J Technol Assess Health Care; 2015 Jan; 31(1-2):86-9. PubMed ID: 25989920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Health Economic Modelling - Optimizing Development for Medical Device Developers? Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling".
    Teljeur C; Ryan M
    Int J Health Policy Manag; 2020 Sep; 9(9):403-405. PubMed ID: 32610765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis at the development phase of a potential health technology: examples based on tissue engineering of bladder and urethra.
    McAteer H; Cosh E; Freeman G; Pandit A; Wood P; Lilford R
    J Tissue Eng Regen Med; 2007; 1(5):343-9. PubMed ID: 18038428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is a new drug worth? An innovative model for performance-based pricing.
    Dranitsaris G; Dorward K; Owens RC; Schipper H
    Eur J Cancer Care (Engl); 2015 May; 24(3):313-20. PubMed ID: 25256668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer.
    Garrison LP; Veenstra DL
    Value Health; 2009; 12(8):1118-23. PubMed ID: 19624617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of research and value of development in early assessments of new medical technologies.
    Retèl VP; Grutters JP; van Harten WH; Joore MA
    Value Health; 2013; 16(5):720-8. PubMed ID: 23947964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early assessment of medical technologies to inform product development and market access: a review of methods and applications.
    Ijzerman MJ; Steuten LM
    Appl Health Econ Health Policy; 2011 Sep; 9(5):331-47. PubMed ID: 21875163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of economic evaluation to decision making in early phases of product development: a methodological and empirical review.
    Hartz S; John J
    Int J Technol Assess Health Care; 2008; 24(4):465-72. PubMed ID: 18828942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.